Anakinra as first-line monotherapy for new-onset steroid-naïve sJIA patients-Reference-Cited by-同舟云学术

Anakinra as first-line monotherapy for new-onset steroid-naïve sJIA patients

Published:2024-07-30 Issue: Volume: Page:1-3
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Mastrolia Maria Vincenza¹²,Abu-Rumeileh Sarah³,Maccora Ilaria¹²^ORCID,Maniscalco Valerio¹,Marrani Edoardo¹,Pagnini Ilaria¹,Taddio Andrea⁴,Simonini Gabriele¹²

Affiliation:

1. Rheumatology Unit, ERN ReCONNET center, Meyer Children’s Hospital IRCCS, Firenze, Italy

2. NEUROFARBA Department, University of Florence, Firenze, Italy

3. Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

4. Institute for Maternal and Child Health IRCCS Burlo Garofolo, and University of Trieste, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2024.2384703

Reference16 articles.

1. Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies

2. Effectiveness of First-Line Treatment With Recombinant Interleukin-1 Receptor Antagonist in Steroid-Naive Patients With New-Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study

3. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series

4. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

5. Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study